Navigation Links
Excellims IA3100 High Performance Ion Mobility Spectrometer Wins R&D 100 Award
Date:7/15/2014

instruments based on an array of novel patented approaches in the IMS field.”

Besides the IA3100, Excellims offers a series of high performance ion mobility spectrometry products, including: GA2100, a standalone HPIMS for rapid on-site chemical analysis; RA4100, an integrated HPIMS quadrupole MS system; and the newly introduced MA3100, a high performance ion mobility pre-filter that is easily added on to existing MS systems.

Excellims Corporation, Acton, Massachusetts, USA, is a world leader for high performance ion mobility spectrometry technology. Excellims was founded in 2005 by Dr. Ching Wu and Mr. Paul Eisenbraun, veterans in the ion mobility spectrometry industry. Excellims researches, develops, manufactures, and markets high performance ion mobility spectrometers (HPIMS™). Excellims products offer fast and easy solutions for chemical analysis. More importantly, combined with other analytical technologies, Excellims’ HPIMS provides a new dimension for analytical chemical separation that is otherwise not possible in routine chemical analysis today. For additional information, please visit http://www.excellims.com.

###

Read the full story at http://www.prweb.com/releases/2014/07/prweb12015831.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Arizona State University engineers aim to improve performance of technology in extreme environments
2. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
3. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
4. McLean Report on nanotechnology that may enhance medication delivery and improve MRI performance
5. New Daily Disposable Multifocal Contact Lenses from CooperVision Offer Comfort, Performance, Health, and Convenience to Fit Your Life
6. Maxx Performance Joins GreenPalm to Promote Sustainable Harvest of Palm Oil
7. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
8. A KAIST research team has developed a high performance flexible solid state battery
9. Elsevier Launches New Journal: Performance Enhancement & Health
10. Nanoresonators might improve cell phone performance
11. New design could improve condenser performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... NWBS and NWBT; OTC Bulletin Board: NWBO) (the,"Company") announces ... Holdings,through the subscription of 1,000,000 new shares in the ... The new stock is expected to be admitted ... will not be tradable on the,Company,s OTC bulletin board ...
... (TSX-V: ICO) is pleased to announce the completion of ... company with sufficient capital to develop iCo-007 through to ... is targeting the treatment of Diabetic Macular Edema. The ... working capital. iCo,s partner Isis Pharmaceuticals Inc., (NASDAQ: ...
... Technologies (Celsis,IVT), a division of Celsis International plc, ... and Wisconsin-based Promega Corp,will take the trial and ... Celsis IVT is pre-qualifying lots of its extensive ... including,the P450-Glo(TM) CYP Assay used to study cytochrome ...
Cached Biology Technology:Northwest Biotherapeutics Secures $700,000 Equity Financing 2iCo Therapeutics Closes $1.3 Million Private Placement 2iCo Therapeutics Closes $1.3 Million Private Placement 3Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... largest and fastest growing open-access publishers, today announces the ... . A broad scope journal covering all specialties, ... and interactive web platform for the research community to ... Frontiers, real-time and interactive peer-review enables fast, fair and ...
... detection and destruction by the immune system. Stimulation of the ... are many factors that cause the immune system to ignore ... to suppress the immune system response. In this issue of ... Ronald Levy at Stanford University found that regulatory T cells ...
... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ...
Cached Biology News:Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3Please do try this at home 2
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Request Info...
Biology Products: